VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
-17.47%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$1.18B
AUM Growth
+$1.18B
(-19%)
Cap. Flow
+$80.9M
Cap. Flow
% of AUM
6.89%
Top 10 Holdings %
Top 10 Hldgs %
76.08%
Holding
41
New
4
Increased
4
Reduced
7
Closed
4
Top Buys
| 1 |
MTSR
Metsera, Inc. Common Stock
MTSR
|
$102M |
| 2 |
Solid Biosciences
SLDB
|
$9.18M |
| 3 |
Savara
SVRA
|
$9.02M |
| 4 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$8.85M |
| 5 |
Surrozen
SRZN
|
$7.38M |
Top Sells
| 1 |
Merus
MRUS
|
$24.9M |
| 2 |
Aquestive Therapeutics
AQST
|
$9.36M |
| 3 |
4D Molecular Therapeutics
FDMT
|
$7.35M |
| 4 |
Oric Pharmaceuticals
ORIC
|
$6.76M |
| 5 |
Terns Pharmaceuticals
TERN
|
$5.97M |
Sector Composition
| 1 | Healthcare | 99.34% |
| 2 | Financials | 0.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apogee Therapeutics
APGE
$2.17B
| $317M | 27% | 8,493,321 | – | – |
|
|
MTSR
2
Metsera, Inc. Common Stock
MTSR
$3.71B
| $102M | 8.69% | +3,750,662 | New | +$102M |
|
3
Ocular Therapeutix
OCUL
$2.12B
| $93.5M | 7.96% | 12,762,462 | – | – |
|
4
Enliven Therapeutics
ELVN
$1.2B
| $79.2M | 6.74% | 4,026,331 | – | – |
|
5
KalVista Pharmaceuticals
KALV
$678M
| $77.4M | 6.58% | 6,703,985 +454,254 | +7% | +$5.24M |
|
6
Viridian Therapeutics
VRDN
$1.5B
| $52.3M | 4.45% | 3,882,709 | – | – |
|
7
Pharvaris
PHVS
$1.39B
| $48.9M | 4.16% | 3,112,720 -107,410 | -3% | -$1.69M |
|
8
Spyre Therapeutics
SYRE
$996M
| $43.3M | 3.69% | 2,685,448 | – | – |
|
|
ORKA
9
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $42.6M | 3.62% | 4,148,428 +862,808 | +26% | +$8.85M |
|
10
Praxis Precision Medicines
PRAX
$958M
| $37.5M | 3.19% | 989,985 | – | – |
|
11
Cogent Biosciences
COGT
$1.69B
| $34M | 2.9% | 5,684,411 | – | – |
|
12
Dianthus Therapeutics
DNTH
$759M
| $31.6M | 2.69% | 1,744,373 | – | – |
|
13
Dyne Therapeutics
DYN
$1.92B
| $22.7M | 1.93% | 2,173,913 | – | – |
|
14
Cidara Therapeutics
CDTX
$1.66B
| $22.6M | 1.93% | 1,051,518 +285,795 | +37% | +$6.16M |
|
15
enGene Holdings
ENGN
$236M
| $22.6M | 1.92% | 5,046,414 | – | – |
|
16
Erasca
ERAS
$445M
| $22.2M | 1.89% | 16,216,216 | – | – |
|
|
17
Oric Pharmaceuticals
ORIC
$994M
| $17.8M | 1.51% | 3,182,527 -1,212,000 | -28% | -$6.76M |
|
|
UPB
18
Upstream Bio, Inc. Common Stock
UPB
$923M
| $14M | 1.2% | 2,295,319 | – | – |
|
19
Astria Therapeutics
ATXS
$349M
| $13.1M | 1.12% | 2,457,348 | – | – |
|
20
Cullinan Oncology
CGEM
$445M
| $10.4M | 0.89% | 1,379,965 | – | – |
|
|
21
Solid Biosciences
SLDB
$427M
| $9.18M | 0.78% | +2,481,400 | New | +$9.18M |
|
|
22
Savara
SVRA
$567M
| $9.02M | 0.77% | +3,257,639 | New | +$9.02M |
|
|
ABVX
23
Abivax
ABVX
$6.12B
| $8.41M | 0.72% | 1,345,780 | – | – |
|
|
PCSC
24
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $7.73M | 0.66% | 750,000 | – | – |
|
|
25
Surrozen
SRZN
$104M
| $7.38M | 0.63% | +632,931 | New | +$7.38M |
|